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Summary 
Type II major histocompatlblllty complex combined 
immune deficiency (type II MHC CID or bare lympho- 
cyte syndrome) Is a congenital immunodeficlency dis- 
ease characterized by absent MHC class II expression. 
Four distinct complementation groups have been iden- 
tified. Recently, the defective gene In group II type II 
MHC CID has been Isolated and termed CIITA. Here, 
we demonstrate that CIITA Is an MHC class II gene- 
specific transcription activator. The transcription acti- 
vation function is provided by the N-terminal acidic 
domain (amino acids 2&137), which Is experimentally 
exchangeable with a heterologous viral transcrlption- 
activating domain. The specificity of CIITA for three 
major YHC class II genes, DR, DQ and DP, is mediated 
by Its remaining C-terminal residues (amino acids 317- 
1130). The transactivatlon of multiple cis elements, 
especially S and X2, of the DRa proximal promoter in 
group II CID cells is CIITA dependent. Since CIITA over- 
expression in normal cells did not increase class II ex- 
pression, we propose that initiation of CIITA expres- 
sion serves as the on-off switch, while availability of 
downstream lnteractor(s) limits transcription. 
Introduction 
Major histocompatibilty complex (MHC) deficient com- 
bined immune deficiency (CID, or bare lymphocyte syn- 
drome) is one form of autosomal recessive hereditary se- 
vere combined immunodeficiency disease. Patients with 
this disease usually have normal numbers of T and B lym- 
phocytes and normal mitogenic responses but reduced 
numbers of CD4+ T cells. They are unable to respond to 
T helper-dependent antigens, leading to recurrent viral 
and bacterial infections and death in early childhood un- 
less provided with heterologous bone marrow transplants 
(Rijkers et al., 1987; Hume et al., 1989; Touraine et al., 
1992). This disorder has been attributed to defects in ex- 
pression of MHC antigens, known for their fundamental 
function in mediating T cell development and activation 
(von Boehmer, 1994; Nossal, 1994; Germain, 1994). MHC 
gene expression deficiencies in MHC CID may involve 
class I antigens (type I), class II antigens (type II), or both 
(type Ill) (Touraine et al., 1992). In type II MHC CID, the 
defects affect all somatic cells that normally express MHC 
class II antigens, such as B lymphocytes, macrophages, 
dendritic cells, and thymic epithelial cells. These cells lack 
not only proteins but also mRNAs for all MHC class II a 
and 8 chains (dePreval et al., 1988). Since the strut 
genes for these proteins are intact and the MHC locu! 
the disease locus segregate independently, the defel 
type II MHC CID have been postulated to be defe 
transacting factors involved in the regulation of 
class II gene transcription (Hume and Lee, 1989; deP 
et al., 1985; Stimac et al., 1991). 
By fusion complementation analyses using variou 
perimentally derived or patient-derived MHC class II- 
ative cell lines, four different genetic defects have 
found, each sufficient to cause an MHC class II-ne9 
phenotype (Benichou and Strominger, 1991; Seidl ( 
1992). In vivo footprinting analyses at MHC class II 
DRB, and DQp gene promoters revealed two predom 
promoter phenotypes (Kara and Glimcher, 1991,19 
The first in vivo phenotype, observed in cells from COI 
mentation groups I, Ill, and IV, is characterized by a 
plete lack of factor binding at all promoter elemer 
each examined gene (the bare phenotype), indicatin! 
DNA binding factors are either defective in these m 
cells or that their accessibility to DNA is impaired 
and Glimcher, 1991,1993a). The second in vivo pror 
phenotype is characterized by normal DNA-protein 
actions at the Xl , X2, Y, and octamer elements (the 
pied phenotype) and is associated only with complem 
tion group II mutant cell lines (Kara and Glimcher, 19 
indicating a distinct defect at a stage in transcription 
lation other than promoter binding. Indeed, a cDN 
quence termed CIITA recently has been isolated 
MHC class II-positive Raji cells (Steimle et al., 1993). 
restores MHC class II expression upon transfectior 
complementation group II mutant cells. Howeve 
mechanism by which CIITA regulates MHC class II 
transcription, like those of other previously isolated 
class II promoter-binding factors (Reith et al., 1989 
et al., 1990; Hooftet al., 1990; Tsanget al., 1990) rer 
to be elucidated. 
Results and Discussion 
The CIITA Protein Has Intrinsic Transcription 
Activation Activity, Which Maps to the 
N-Terminal Acidic Domain 
Sequence analysis of the CIITA open reading fran 
vealed no obvious motifs characteristic of DNA bi 
domains, consistent with its inability to bind in vitro to 
class II DRa promoter DNA (Steimle et al., 1993). An 
minal acidic domain followed by three proline-, serine 
threonine-rich domains was present. Since acidic doI 
are common features of several known transcriptiol 
vators (Cress and Triezenberg, 1991; Pellett et al., 
we wished to test whether CIITA was a transcription a 
tor. The full-length CIITA coding region was fused ( 
stream of the N-terminal 202 residues of the LexA pr 
which retain its dimerization and DNA binding doi 
(Gyuris et al., 1993). The fusion construct was transl 
into a yeast cell, EGY48, pretransformed with a re 
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A 
CIITA or its mutants 
Reporter: 8 LexA binding sites, followed by the ~galsctosidnse gene. 
fbgalactosidase + X-gal = BLUE. 
B 
pSH17-4, positive control. 
pRFHM1, negative control. 
pEGZO.2, cloning vector. 
pEGZOZ.CIITA. 
Figure 1. Detection of Transcription Activity in Full-Length CllTA Re- 
combinant Protein Expressed in Yeast 
To test whether the CIITA protein is a transcription activator, the full- 
length CllTA coding region (except the first methionine residue) was 
fused downstream of the LexA N-terminal dimerization and DNA- 
binding domains. The fusion construct was assayed with a reporter, 
pSH16-34, in a yeast host, EGY46. pSH16-34 contains the GAL1 
promoter fused to IacZ in which the GAL1 enhancer-like upstream 
activating sequence (UAS) has been replaced with binding sites for 
eight LexA dimers. pEG202 is the vector for constructing LexA-CIITA 
test fusion, and pSH17-4 and pRFHM1 are positive and negative con- 
trols, respectively. pSH17-4 expresses a LexAGAL4 fusion that acti- 
vates transcription. pRFHM1 expresses LexA fused to a transcription- 
ally inert fragment of the Drosophila bicoid product. These constructs 
have been described in more detail previously (Gyuris et al., 1993). 
construct containing the LacZ reporter gene under the 
control of eight LexA-binding sites (Gyuris et al., 1993). In 
initial experiments, the LexA202-CIITA full-length fusion 
protein activated the transcription of the 8-galactosidase 
@-gal) gene as evidenced by the blue color changes of 
colonies on X-gal containing selective plates (Figure 1). 
Further definition of the functional domains of the CIITA 
protein was thus performed. LexA202-CIITA deletion fu- 
sion mutants were made and tested for transcriptional acti- 
vation using the herpes simplex virus 1 (HSVl , strain F) 
a trans-inducing factor C-terminal transcription activation 
domain (Pellett et al., 1985) as a reference. 
The quantitative P-gal assay results presented in Figure 
2 show that as few as 114 N-terminal residues of CIITA 
(10% of the full-length protein) are sufficient to activate 
reporter gene transcription when a DNA binding motif is 
provided. The downstream proline-, serine-, and threo- 
nine-rich domains are not required for this activity, as no 
statistically significant effect was observed in their pres- 
ence or absence (data not shown). In contrast, LexA fusion 
proteins containing as many as 830 C-terminal residues 
of CIITA (73% of the full-length protein) do not have com- 
parable transcription activating activity. The presence of 
the C-terminal residues downstream of the proline-, ser- 
ine-, and threonine-rich domains actually has a significant 
inhibitory effect on the potency of N-terminal transcription 
activation activity. Removal oftwo-thirdsof C-terminal resi- 
dues resulted in a 4-fold increase in its transcription acti- 
vating activity (Figure 2; p < 0.02). These results suggests 
that the N-terminal acidic domain of CIITA likely mediates 
its interaction with proteins responsible for general eukary- 
otic transcription, e.g., the basic domain of TFIID (Bura- 
towski and Zhou, 1993). This fits well with the observations 
that group II MHC class II-negative cells have normal pro- 
moter occupancy (Kara and Glimcher, 1993a) and that 
CIITA itself does not bind to MHC class II promoters 
(Steimle, et al., 1993) and thus led us to hypothesize that 
the C-terminal residues downstream of the acidic domain 
of CIITA must be responsible for mediating MHC class II 
gene-specific transcription. 
The CIITA C-Terminal Residues Direct Specific 
Transcription from the Human MHC Class II DRa 
Promoter, while the Proline-, Serlne, and 
Threonlne-Rich Domains Are Not Sufficient, 
nor Necessary for this Function 
Since neither the proline-, serine-, and threonine-rich do- 
mains that follow the N-terminal acidic domain, nor the 
downstream C-terminal residues, are required for general 
transcription activation, it is possible that they are involved 
in mediating the specific activation of MHC class II gene 
transcription. Chimeric CIITA and truncated CIITA mu- 
tants were thus constructed. First, to test whether the 
acidic domain of CIITA is a transcription activator in mam- 
malian cells as well as in yeast, a chimeric construct, 
pGAL4-CIITA.N330, was made, in which the CIITA N-ter- 
minal acidic domain, along with the proline-, serine-, and 
threonine-rich domains, was fused downstream of the 
GAL4 C-terminal DNA-binding domain (Keegan et al., 
1988). Second, to determine whether the proline-, serine-, 
and threonine-rich domains, which share similarities with 
domains involved in transcriptional activation via protein- 
protein interactions in a number of transcription factors or 
coactivators such as Spl , TAFl 10, and BCW (Pascal and 
Tjian, 1991; Hoey et al., 1993; Bours et al., 1993) would 
be sufficient to mediate the specific activation of MHC 
class II genes, a construct with a C-terminal truncated 
mutant CIITA, pCMV.CIITA.N330, was made, which re- 
tains only the CIITA N-terminal acidic and proline-, serine-, 
and threonine-rich domains. Third, to test whether the 
CIITA C-terminal downstream residues, in the absence 
of the proline-, serine-, and threonine-rich domains, can 
mediate specific MHC class II gene transcription, a chi- 
merit construct, pCMV.aTIF-CIITAC813, was made, in 
which the entire CIITA N-terminal acidic domain and the 
proline-, serine-, and threonine-rich domains have been 
substituted by the 75 C-terminal residues of the HSVI a 
trans-inducing factor transcription activation domain. The 
transcription-activating activity and promoter specificity of 
these recombinant CIITA proteins were assayed using 
chloramphenical acetyltransferase (CAT) reporter con- 
structs under the control of either the GAL4 protein recog- 
nition sequence or the MHC class II DFla promoter proxi- 
mal sequence. 
As seen in the quantitative CAT assay results summa- 
rized in Figure 3, the N-terminal acidic domain of CIITA 
indeed provides a significant transcription activation in hu- 
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man B lymphoid cells (Figure 3, lane 2) and the down- 
stream proline-, serine-, and threonine-rich domains are 
not sufficient to direct transcription from the MHC class 
II DRa promoter (Figure 3, lanes 7 and 10). Strikingly, the 
C-terminal 813 residues (72% of the CIITA protein) are 
not only necessary but also sufficient to provide the speci- 
ficity for transcription from the MHC class II DRa promoter 
when a general transcription activating activity is provided 
by the heterologous HSVl a trans-inducing factor (Figure 
3, lanes 8 and 11) (p < 0.005), although the activity was 
lower than that observed with the intact CIITA (Figure 3, 
lanes 9 and 12). This decrease in transcription activating 
potency may be due to an altered less favorable conforma- 
tion of the chimeric CIITA protein. That this activity is pro- 
moter specific is also demonstrated by the failure of the 
aTIF-CIITAC813 chimeric protein and the wild-type CIITA 
Figure 2. Quantitative Mapping of the 
Transcription Activation Domain 
To map the transcription activation dom 
the CllTA protein, the N-terminal and 
minal deletion mutants of CIITA were 
downstream of the LexA N-terminal dim 
tion and DNA-binding domains. These 
structs were transfected into EGY48, 1 
had been transformed with pSH18-34. 
scription activation waadetermined by gn 
the transformants on X-gal selective l 
(data not shown) and by measuring p-gal 
ity in cell lysates as previously desc 
(Reynolds and Lundblad, 1994). The pn: 
serine-, and threoninerich domains of 
are residues 163-195, residues 209-237 
residues 261-322 as previously desr 
(Steimleetal., 1993). Thedefinitionofthe 
minal acidic domain has been modified 8! 
dues 26-137, instead of residues 52 
(Steimle et al., 1993) to include anoths 
evenly spaced upstream glutamic acic 
aspartic acid residues. The data for two e 
ments, each with four duplicates, are sh 
protein to activate the GALCdriven CAT reporter cons 
(Figure 3, lanes 5 and 8). It appears therefore tha 
function of the C-terminal portion of CIITA is to me’ 
the observed specific activation of transcription from I 
class II DRa promoter. 
Restoration of MHC Class II Surface Expression 
In MHC Class II-Negative B Cells by a Chlmerlc 
Fusion bstween the CIITA C-Terminal Residues a 
Heterologous Virus-Derived Transcription 
Activation Domain 
To extend our observations with the GAL4 and the 
test promoters to the endogenous MHC class II ge 
these constructs were subsequently transfected into I 
class II-negative cells from complementation groi 
RM3 (Benichou and Strominger, 1991) and clone 13 
Figure 3. TheCllTAN-Terminal Residue 
vide Transcription Activation and the r 
minal Residues Provide Class II Pro 
Specificity in B-Lymphoid Lineage Cell I 
The MHC class II-positive B lymphom 
line, Raji, and mutant class II-negativ 
lines, RM3 and clone 13, were transfeci 
electroporation (BioRad electroporator 
pF, 0.25 kV) with 10’ cells and 5 pg D 
the test construct, the reporter constru 
both in 0.4 cm cuvettes. Cells were kl 
RPM 1640 supplemented with glutamin 
10% fetal calf serum and antibiotics. Af 
hr, the transfectants were harvested ar 
sayed for CAT activity following a mc 
phase extraction protocol (Sheen, 1989 
promoters for the CAT reporter gene are t 
lined. TheCAT activities have been norm 
in reference to that of the marked 
(marked with asterisk) of the same cell 
The results of three experiments, eacl 
three duplicates, are shown. 
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Figure 4. Endogenous MHC Class II Gene Transcription Is Directed by the Carboxyl Residues of CIITA 
Type II MHC CID complementation group II Epstein-Barr virus (EBV)-transformed B cell lines, clone 13 and RM3, and the MHC class II-positive 
BurkiWs lymphoma B cell line, Raji, were each transfected with 5 pg DNA of the constructs described in Figure 2 and of pCMV.CIITA.CS30. These 
three cell lines were also transfected with pCMV.Kb as internal transfection controls. After 45 hr, selection with 450 @ml hygromycin was begun 
and continued for 2 weeks. The resulting stable transfectants were then subjected to immunostaining with anti-DR. anti-DO, anti-DP, anti-HtA 
class I, and anti-murine MHC class I Kb monoclonal antibodies, followed by fluorescence microscopy examination (data not shown) and flow 
cytometry analysis as described (Ctten and Yokoyama, 1994). The antibodies used were LB3.1 (a-DR), Genox or SPV.W (a-W). B7/21 (a-DP), 
W8132 (a-class I). and Y3 (a-p)<“). respectively. Top, Raji stable transfectants; middle, clone 13 stable transfectants; bottom, RMIstable transfectants. 
The test constructs used for each transfection are as indicated. Human MHC class I sewed as the endogenous control and murine MHC class 
I Kb as the transfectiorvselection control in these experiments. Specificity of aTIF-CIITA.CB13 and wild-type CIITA were further tested by FACS 
analysis of stably transfected Raji and clone 13 cells for surface expression level of four additional B cell-specific markers, CD4g 87-1. 87-2, 
and LECAM-1 and no effect was obsewed (data not shown). Results of one representative experiment of four independent transfections are shown. 
et al., 1991). Further, to determine whether the CIITA 
C-terminal residues are sufficient to interfere with the ac- 
tivity of the endogenous CIITA protein, an additional con- 
struct, pCMV.CIITA.C830 in which the N-terminal acidic 
domain of CIITA along with its downstream proline-, ser- 
ine-, and threonine-rich domains have been completely 
removed, was also tested in MHC class II-positive Raji 
cells and DQ positive clone 13 cells (Ono et al., 1991). 
The resulting stable transfectants were assayed for their 
surface expression of the three major MHC class II iso- 
types, DR, DQ, and DP. Flow cytometry analysis (Figure 
4) showed that the promoters of all these MHC class II 
genes, in their native chromosomal configuration, were 
activated by the HSVI aTIF-CIITA.C813 fusion as well 
as by the intact CIITA protein (Figure 4, clone 13 and RM3 
transfectants: DR, DO, and DP columns). Specificity for 
MHC class II genes was clearly observed, since no effect 
of these constructs on surface expression levels of MHC 
class I (Figure 4) or other B cell-specific markers including 
CD40, 87-1, 87-2, and LECAM-1 was observed (data 
notshown). TheCIITAexpression construct, pCMV.CIITA, 
resulted in levels of CIITA protein in clone 13 cells that 
were approximately equal to the level of endogenous CIITA 
protein in Raji cells as demonstrated by Western blot anal- 
ysis with polyclonal antisera against the CIITA N terminus 
(data not shown). However, no significant effect on endog- 
enous CIITA activity by the C-terminal 830 residues alone 
was observed (Figure 4, Raji transfectants: DR, DC, and 
DP columns; clone 13: DC column). The absence of a domi- 
nant-negative effect might imply that an upstream acidic 
domain is necessary to maintain a proper conformation 
for CIITA function or that only a few CIITA molecules are 
necessary to achieve maximal class II expression (see 
discussion below). A heterologous acidic domain is suffi- 
cient to provide such a conformation, although it is not 
optimal as seen in the transfection of clone 13 and RM3 
with pCMV.aTIF-CIITA.C813 (see Figure 3; Figure 4). The 
function of the proline-, serine-, and threonine-rich do- 
mains might be to maintain an optimal conformation as re 
vealed by the reduced transcriptional activity of pCMV.aTIF- 
CllTA.C813 in RM3 and clone 13 when compared with 
those of the intact CIITA. However, they are not essential 
Distinct Functional Domains of CIITA 
549 
Figure 5. Functional Domains of CIITA 
The transcription activation domain and the interaction domain of CI- 
ITA are functionally characterized asdescribed in the text. The deletion 
found in RJ2.25 CIITA involves residues 330-934 and the deletion 
found in BLS-2 CIITA involves residues 940-963. Both deletions result 
in an MHC class II-negative phenotype (Steimle et al., 1993), without 
affecting MHC class II gene promoter in vivo footprints (Kara and 
Glimcher, 1991, 1993). This figure is drawn to scale. 
for general transcription activation (see Figure 2), nor are 
they sufficient to provide MHC class II gene specificity 
(see Figure 3; Figure 4). 
These results explain the absence of MHC class II ex- 
pression in two mutant cell lines, RJ2.25, BLS-2, in com- 
plementation group II (Steimle et al., 1993). The mutations 
in the radiationderived RJ2.25 cell line resulted in a com- 
plete loss of one allele and a major deletion in the other, 
involving the majority of the C-terminal residues of CIITA, 
which are essential for MHC class II gene specificity. The 
major mutation in the patient-derived cell line, BLS-2, was 
a defective splice donor, resulting in a deletion of residues 
940-963 (Figure 5). In both cases, the deletions may dis- 
rupt the conformation required for MHC class II gene- 
specific transcription regulation by the CIITA protein, 
which recruits proteins responsible for general eukaryotic 
transcription. Thus, we conclude that CIITA is an k 
class II gene-specific transcription activator whose g 
specificity is mediated by the carboxyl terminal resic 
(amino acids 317-l 130) and whose transcription ac 
tion activity derives from the N-terminal acidic don 
(amino acids 26-137) (Figure 5). 
CIITA Trsnsactivatlon Involves Multiple cis 
Elements In the DRa Proximal Promoter 
It has been shown that certain cell lines (RJ2.25, A 
in group II CID do not allow the expression of cla! 
promoter-driven reporter constructs and that this ma! 
theclass H proximal promoter (Calman and Peterlin, 1’ 
Koch & al, 1968; Sloan and Boss, 1966; Riley and B 
1993). To determine the region of the class II prom 
necessary for transactivation by CIITA in clone 13 c 
the following experiment was performed. Clone 13 I 
were stably transfected with a wild-type CllTA cDNl 
as a control, with the mouse Kb cDNA, both driven b) 
CMV promoter. As expected, clone 13 cells transfe 
with the wild-type CIITA expressed surface DR, DP, 
while Kb-transfected clone 13 cells were only DQ pos 
(see Figure 4). Those stably transfected clone 13 I 
were then transiently transfected with a DRa promc 
CAT reporter construct containing the -174 to +4! 
region of the proximal promoter, a region which con! 
the S, Xl, X2, Y, and Ott cis regulatory elements. 
Kb-transfected clone 13 cells expressed a very low I: 
level of the reporter gene activity, while the wild- 
CIITA-transfected clone 13 cells expressed much hi 
level CAT activity, demonstrating that CIITA is neces 
for high level transcriptional activity of the proximal 
promoter (Figure 3, lanes 11 and 12). To map furthe 
cis elements required for transactivation by CIITA, 
Figure 6. Mapping of CIITA-Dependent I 
latoty cis Elements in the MHC Class II 
Proximal Promoter 
CAT reporter constructs under the conl 
the wild-type DRa proximal promoter (-1 
+45) or its derivatives with mutations 
duced into the S, Xl, X2. Y, and Ott regu 
elements were transfected into done 13 
stably transfected with either pCMV.1 
pCMV.CIlTA. The transfected ceils wen 
vested 49 hr later and CAT activity of ea 
sate was determined. (1) The relative al 
was calculated by nonalizing the CAT a 
of each cell lysate in reference to that ( 
lysate transfected with the wild-type p 
CAT reporter (lanes 1 or 7, for clone 13 
CIITA stable transfectants). (2) This val 
fleets the average relative activity norm 
using the activity of the lysate from clo 
pCMV.CIITA stable transfectant tram 
transfected with the wild-type pDRa-CI 
porter (lane 12). (3) This ratio was calc~ 
by dividing the R activity of a parlicula 
mutant promoter in the CIITA stable traI 
tant by that of the same mutant promoter 
Kb stable transfectant. The one furthes 
1 .O indicates the highest dependence on 
transactivation. 
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promoter constructs containing mutations in the S, Xl, 
X2, Y, and Ott elements, which prevent binding of the 
cognate factors as demonstrated by in vivo genomic foot- 
printing experiments (Kara and Glimcher, 1993a), were 
transfected into Kb- or CIITA-transfected clone 13 cells. 
Each of these mutants resulted in a significant decrease 
in reporter gene activity in CIITA-transfected clone 13 
cells, with the S box mutation causing the most dramatic 
reduction. Although the levels of CAT activity are low in 
the Kb-transfected clone 13 cells as expected, it appears 
that the mutation of certain cis elements causes a further 
decrease (see the average relative activity column in Fig- 
ure 6). If one compares the effects of the mutation of each 
cis element in Kb versus CIITA-transfected clone 13 cells, 
a ratio furthest from 1 .O would indicate the most depen- 
dence on CIITA. Thus, the S and X2 elements appear 
to be highly CIITA dependent, although all of these cis 
elements are involved to a greater or lesser degree, in- 
dicating that multiple factors that bind to the proximal 
promoter are involved in CIITAdependent class II tran- 
scription. 
Separation of CIITA into two essential functional do- 
mains establishes a critical link between general eukaryo- 
tic transcription activation and the specific regulation of 
human MHC class II gene transcription. Since the CIITA 
protein does not itself bind to DNA, it is likely that the 
specific regulation of MHC class II gene transcription is 
achieved by an interaction of the C-terminal portion of 
CIITA with already cloned or, as yet unidentified, MHC 
class II promoter DNA binding proteins. This would be 
reminiscent of the HAP2/HAP3/HAP4 system in Saccha- 
romyces cerevisiae, where HAP2 and HAP3 bind as a 
transcriptionally inert heteromeric complex to the CCAAT 
box of the CYCl gene: interaction of HAP4, which itself 
does not bind DNA, provides transcriptional activity (Fors- 
burg and Guarente, 1989). The identity of the proteins that 
interact with CIITA is not yet known. Since the proximal 
promoter region (-174 to +45) can be transactivated by 
CIITA (see Figure 3) and since this region in multiple MHC 
class II genes has been shown to confer tissue-specific 
and cytokine inducibility (Tsang et al., 1990; Sherman et 
al., 1987; Vilen et al., 1991; Moses et al., 1992; Sloan and 
Boss, 1988), factors (such as RF-X, hXBP-1, NF-YA, B) 
that bind to this region may be important. Indeed, our ex- 
periments in CIITA-transfected clone 13 cells versus con- 
trol Kb-transfected clone 13 cells suggest that interaction 
with factors that bind to the S and X2 elements are espe- 
cially important, although other elements (Xl, Y, and Ott) 
are also involved (Figure 6). Clues derived from the mutant 
cell lines in other type II MHC class II CID patients may 
also prove informative. Thus, transfection of wild-type 
CIITA into mutant cells in these other complementation 
groups does not restore MHC class II gene transcription 
(Steimle et al., 1993), suggesting that the defects associ- 
ated with these groups likely involve a step(s) downstream 
of CIITA. While the data in this report focus on downstream 
events of class II MHC transcription, understanding the 
control of upstream events, i.e., the control of CIITA tran- 
scription, will also be of considerable interest, since its 
expression is so tightly correlated with class II expression 
NA 
Specitic Regulated transcription 
Figure 7. Proposed Model of MHC Class II Gene Transcription Regu- 
lation 
We suggest that the initiation of CIITA expression serves as the on- 
off switch for MHC class II gene expression, while the availability of its 
downstream interactor acts lo limit the rate of transcription. Straight 
solid lines represent genes and boxes represent upstream regulatory 
sequences. The figure is a schematic presentation of the hypothesis. 
It has been shown that all the cognate factors that bind to the proximal 
promoter of DRa class II gene are involved in CIITA-dependent tran- 
scription activation (Figure 6). 
(Steimle et al., 1993,1994; Chang et al., 1994; Chang and 
Flavell, 1994). Although the CIITA gene is transcribed at 
very low levels in MHC class II-positive cells (Steimle et 
al., 1994), and interferon-y (IFNy) induces CIITA mRNA 
prior to the induction of class II MHC transcripts, a process 
recently shown to involve the STAT IFNy(STAT1 [p91] and 
STAT2 (~841) and more distal jak tyrosine kinase proteins 
(Steimle et al., 1994; Chang et al., 1994; Muller et al., 
1993; Darnell et al., 1994), we did not observe any increase 
in surface levels of MHC class II DR, DO, and DP antigens 
upon overexpression of CIITA in Raji cells (data not 
shown). Combining this observation and the data pre- 
sented in Figure 6, we propose a model of specific MHC 
class II gene transcription regulation in which the initiation 
of CIITA expression serves as the on-off switch for MHC 
class II gene expression, while the availability of its down- 
stream interactor acts to limit the rate of transcription 
(Figure 7). Characterization of both the upstream path- 
ways and the downstream defects responsible for groups 
I, Ill, and IV CID should reveal the mechanism by which 
CIITA specifically activates MHC class II gene transcrip- 
tion. The molecular dissection of CIITA reported here also 
defines specific targets for developing therapeutics. Drugs 
that disrupt the interactions between CIITA and other, yet 
to be identified, upstream or downstream MHC class II 
transcription regulators serve as potential candidate thera- 
peutics for down-regulating the expression of MHC class 
II alleles associated with autoimmune disorders. 
Experlmental Procedures 
Constructions of the LexA-CIITA Fuslon Plssmld 
and Its Deletion Detivstlves 
The full-length CIITA and LexA fusion expression construct, pEG.CIlTA. 
was made from two intermediate constructs: pEG.CIITA.Sall and 
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pTrc.CIITA. To construct pEG.CIITA.Sall, pEG202 was linearized with 
Sall, dephosphorylated with calf intestine phosphatase; and ligated 
with the Sal1 CIITA fragment derived from pKS.CIITA. Its BamHl frag- 
ment (its 5’ site in pEG202 multiple cloning sites and the 3’ site in 
CllTAcoding region, nucleotide 3048) wassubsequently replaced with 
that of pTrc.CIITA and the resulting construct was termed pEG.CIITA 
after confirming the insert orientation with EcoRI-Notl coordinates. 
The pTrc.CIITA used here was originally designed for recombinant 
CIITA overexpression in bacteria. It was made by inserting a poly- 
merase chain reaction (PCR) fragment encoding the N-terminal 31% 
CIITA into the BamHl and Xhol sites of pTrcHis C (Invitrogen) and 
subsequently replacing the Dralll-Xhol fragment of the resulting 
pTrc.CIITA.N350 with the Dralll-Seal fragment of CIITA. The se- 
quence for the 5’ back primer used in the PCR experiments is AATG- 
GATCcgttgcctggctcca (upper case letters indicating that the tagged 
sequence includes a BamHl site for in-frame cloning) and that for 
the 3’ forward primer is CCGCTCGAGcggcaccatacgtgt (the tagged 
sequence includes an Xhol site). These primers were used with full- 
length CIITA cDNA template in PCR to generate a 1080 bp fragment. 
The PCR reaction profiles were three cycles at 95“C for 5 min, 55°C 
for 5 min, and 72OC for 3 min; followed by thirty cycles at 95OC for 1 
min, 80°C for 2 min. and 72OC for 1 min. 
pEG.CIITA.N789 contains the N-terminal 789 residues of CIITA 
( - 70% of the full-length protein) and was made by linearizing pEG202 
with Xhol, blunting with T4 polymerase, redigesting with BarnHI, and 
ligating with an insert prepared by digesting pET.CIITA with Kpnl, 
blunting with T4 polymerase. and digesting again with BamHI. The 
pET.CIITA used in the pEG.CIITA.N789 construction is another con- 
struct designed for recombinant CIITA overexpression. It was made 
by cloning the CIITA open reading frame, as in the construction of 
pEG.CIITA(above), intopET28c(Novagen). pEG.CIITA.N843wntains 
the N-terminal 848 residues of CIITA (58.9% of the full-length protein) 
and was similarly made as pEG.CIITA.N789 except that pET.CIITA 
was first digested with Sfil in insert preparation. pEG.CIITA.N350 
contains the N-terminal 350 residues of CIITA and was made as 
pTrc.CIlTA.N350. pEG.CIITA.N259, pEG.CIITA.Nl97, pEG.CIITA.Nl51, 
and pEG.CIITA.Nl14 similarly contain the N-terminal 259, 197, 151, 
and 114 residues of CIITA (22.9%. 17.4%, 13.4%, and 10.1% of the 
full-length protein, respectively, and the prolina, serine, and threo- 
nine-rich domains are consequently removed). They were constructed 
by digesting the CllTA-containing Nhel-Xhol fragment (the Nhel site 
is located several nucleotides upstream of the BamHl site in pTrcHic 
C vector) of pTrc.CIITA.NI50 with Banl, Eael, Mspl. and EcoNI, re- 
spectively, blunting with T4 polymerase, and digesting again with 
BarnHI; the vector DNA for these inserts were prepared by linearizing 
pEG202 with Xhol (except WI for pEG.CIITA.NlSl). blunting with T4 
polymerase, and digesting again with BamHI; the inserts and vectors 
were subsequently ligated in frame. The stop codons for these C-ter- 
minal deletion mutant fusion proteins are all provided by the immediate 
downstream sequence of the vector. 
pEG.CIITA.C830 and pEG.CIITAC338 wntain the C-terminal 830 
and 338 residues of CIITA (73.5% and 29.9% of the full-length protein, 
respectively). They were made by linearizing pEG202 with BarnHI, 
blunting with T4 polymerase, digesting again with Sall, and subse- 
quently ligating with the insert prepared by digesting pCMV.CIITA with 
Sphl or Kpnl, blunting with T4 polymerase, and digesting again with 
Sall. pEG.CIITAC580 wntains the C-terminal 580 residues of CIITA 
and was similarly made by linearizing pEG202 with EcoRI, blunting 
with T4 polymerase, cutting again with Sall, and ligating with an insert 
prepared by digesting pCMV.CIITA with Nwl, blunting with T4 poly- 
merase, and digesting with Sall. pEG.CIITA.CI52 contains the Cter- 
minal 152 residues of CIITA and was made by deleting the BamHl 
fragment of pEG.CIITA. 
Determlnatlon of Transcrlptlon Activation Activity 
of LexA Fusion Protelns 
To determine the transcription activation activity of each test protein, 
the LexA fusion constructs were transformed into a yeast host, EGY48 
which has been transformed with a reporter, pSHl&34. The trans- 
formants were then patched onto X-gal containing plates grown at 
30°C for 2-5 days. Transcription activation isvisualized by the appear- 
ance of blue color from the activity of the resulting &gal. 
The reporter, pSH18-34, contains the GAL1 promoter fused to IacZ 
in which the GAL1 enhancer-like upstream activating sequence 
been replaced with binding sites for eight LexA dimers. pEG2 
the vector for constructing LexA-CIITA test fusion, and pSH17-4 
pRFHM1 are positive and negative controls, respectively. pSH 
expresses a LexA-GAL4 fusion that activates transcription. pRF 
expresses LexA fused to a transcriptionally inert fragment of the 
sophila biwid product. These wnstructs have been described in I 
detail previously (Gyuris et al., 1993). 
The other positive control, pEG.aTIF.C78, encodes a LexA-a fr 
protein in which the C-terminal 78 residues (without using the 1 
most C-terminal codons because of later 5’ insertion into the C 
coding region) of HSVI (strain F) a trans-inducing factor transcri~ 
activating domain (Pellett et al., 1985) was inserted downstream c 
LexA dimerization and DNA-binding domains in pEG202. The ins1 
this construct was later used to construct pCMV.aTIF-CI1TA.t 
(see Figure 3). 
To assess the transcription activation activity of each CIITA 
struction quantitatively, cell lysates of each transformant were ass 
for f3gal activity resulting from the transactivation of Lex&lac 
porter gene in pSHl8-34 by LexA-CIITA fusion proteins as previc 
described (Reynolds and Lundblad, 1994). 
Cell Lines, Trsnsfectlon, and Culture Condltlons 
The MHC class II-positive B lymphoma cell line, Raji and type II I 
CID Epstein-Barr virus-transformed cell lines, RM3 and clone 
were maintained with RPM 1840 supplemented with glutamine, a 
otics, and 10% fetal calf serum as previously described (Kara 
Glimcher, 1993b). Transfections were carried out by electropor 
(BioRad electroporator: 980 pF, 0.25 kV) with 10’ cells and 5 ug 
of the test construct, the reporter construct, or both in 0.4 cm 
cuvettes. Selection of transfectants with hygromycin at 450 pglm 
started 24 hr after electroporation and completed after about 2 WI 
Constructlon of CIITA Expresslon Plasmlds for Assays In 
Human B Cell Lines 
The full-length eukaryotic expression construct, pCMV.CIITA, was I 
by inserting the Spel-Xhol CIITA-containing fragment of pKS.( 
into the Nhel-Xhol sites in pCMV derived from pREP7 (Invitrogs 
replacing its long terminal repeat with the CMV promoter region 
pCDM8 (Invitrogen) (J. Douhan, Ill and L. H. G., unpublished d 
The CIITA chimeric fusion test construct, pCMV.aTIF-CIITA.C 
in which the C-terminal transcription activation domain of HS 
trans-inducing factor has replaced the CIITA N-terminal residue: 
318, was generated by multistep subcloning procedure. First, to 
tate the replacement of the proposed transcription activation dam, 
CIITA, along with the downstream proline-, serine-, and threoninc 
domains, with that of HSVl a, an intermediate construct termed 
CIITA.ATth was made, in which the internal Tthlll I fragment off 
(nucleotides 1454-3913) was deleted. pKS/CIITA.ATth was the 
with Ncol and Aatll, blunted, and ligated in-frame with a DNAfrag 
encoding the C-terminal transcription activation domain of HS 
tram+inducing factor (see Figure 2). This second intermediate 
struct was termed pKS/aTIF-CIITA.ATth. Its aTIF-CIITA-conta 
Not I fragment was then used to replace the corresponding Notl 
ment of pKS/CIITA(+). After confirming the orientation with Sacl c( 
nates, the Spel-Xhol aTIF-CIITA-containing fragment of this thi 
termediate construct was inserted into the Nhel-Xhol sites in p( 
The CIITA C-terminal deletion test construct, pCMV.CI1TA.f 
still contains the N-terminal 330 residues and was made by del 
theinternal Hindlll fragmentofCIITA.Thestopcodonforthistrunc 
peptide is provided by the shifted reading frame downstream c 
most 3’ Hindlll site after recircularization. 
The control promoter construct for CAT assays, pBasic-CAT 
purchased from Promega. pDRa-CAT has been previously desc 
(Kara and Glimcher. 1993a). pGAL4-CAT was a reporter con! 
containing two GAL4 recognition sites upstream of the CAT ge 
Clauss and L. H. G., unpublished data). 
Transient transfectants were harvested 48 hr after electropor 
and assayed for CAT activity following the simple phase extn 
protocol previously described, with a modification of two addil 
back extractions with xylene to reduce background radioac 
(Sheen, 1989). 
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Antlbodles, Immunofluorescence Mkxoscopy, 
snd Flow Cytometry Anaiysls 
The antibodies used were LB3.1 (a-DR), Genox or SPV.LS (a-W), 
B7/21 (a-DP), W6/32 (a-class I), Y3 (a-p), 5C3 (aCD40), aB7-1 
(Freedman et al., 1967). IT2.2 (aB7-2) and DREG-56 (aLECAM-l), 
respectively. Stable transfectants were subjected to immunostaining 
with these monoclonal antibodies, followed by fluorescence micros- 
copy examination and flow cytometry analysis as described (Otten 
and Yokoyama, 1994). 
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